Twist Bioscience (NASDAQ:TWST) Reaches New 52-Week High – Still a Buy?

29 May 2026, 07:57 by Scott Moore · The Cerbat Gem

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report)’s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $66.93 and last traded at $65.11, with a volume of 37627 shares trading hands. The stock had previously closed at $64.87.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Leerink Partners set a $80.00 price target on Twist Bioscience in a research note on Friday, May 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday, March 27th. Barclays increased their price target on Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Guggenheim raised their price objective on Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Finally, Evercore raised their price objective on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $58.00.

View Our Latest Research Report on TWST

Twist Bioscience Stock Performance

The company has a debt-to-equity ratio of 0.03, a current ratio of 2.70 and a quick ratio of 2.42. The firm has a fifty day moving average price of $54.17 and a two-hundred day moving average price of $44.30. The stock has a market capitalization of $4.30 billion, a PE ratio of -51.90 and a beta of 2.22.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. During the same quarter in the previous year, the company posted ($0.66) earnings per share. The company’s quarterly revenue was up 19.3% compared to the same quarter last year. Research analysts expect that Twist Bioscience Corporation will post -1.86 EPS for the current year.

Insider Transactions at Twist Bioscience

In other news, CEO Emily M. Leproust sold 8,061 shares of the stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $65.29, for a total value of $526,302.69. Following the sale, the chief executive officer directly owned 858,887 shares in the company, valued at approximately $56,076,732.23. This represents a 0.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa A. Starovasnik sold 500 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $61.83, for a total value of $30,915.00. Following the completion of the sale, the director owned 25,222 shares in the company, valued at approximately $1,559,476.26. The trade was a 1.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 46,551 shares of company stock valued at $2,566,533. Company insiders own 3.08% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Western Wealth Management LLC purchased a new position in Twist Bioscience during the 1st quarter worth $31,000. Flax Pond Capital LLC purchased a new position in Twist Bioscience during the 1st quarter worth $76,000. Bank of America Corp DE increased its holdings in Twist Bioscience by 46.3% during the 1st quarter. Bank of America Corp DE now owns 584,261 shares of the company’s stock worth $27,764,000 after purchasing an additional 184,907 shares during the period. Oddo BHF Asset Management Sas increased its holdings in Twist Bioscience by 7.6% during the 1st quarter. Oddo BHF Asset Management Sas now owns 145,960 shares of the company’s stock worth $6,936,000 after purchasing an additional 10,310 shares during the period. Finally, California State Teachers Retirement System increased its holdings in Twist Bioscience by 20.6% during the 1st quarter. California State Teachers Retirement System now owns 70,348 shares of the company’s stock worth $3,343,000 after purchasing an additional 12,011 shares during the period.

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.